Why Scientists Are Revisiting a Polarizer

• by Rachana Pradhan

• February 10, 2026

FDA Approves Gedatolisib in Breast Cancer

In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.

• by Kathryn Wighton

• July 14, 2026

• 2 min

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

• by Andrea Surnit

• July 20, 2026

• 3 min